odmj
OncoDaily Medical Journal
ODMJ
3067-6444
OncoDaily Medical Journal
US
6002
10.69690/ODMJ-002-1119-6002
Reviews
Engineering CAR and TCR T-Cells to Overcome Resistance in Cancer Therapy
https://orcid.org/0009-0008-5819-6364
Tavadyan
Mane
Yerevan Mkhitar Heratsi State Medical University, Yerevan, Armenia
tavman2003@mail.ru
19
11
2025
ODMJ-002-1119-6002
Copyright (c) 2025 OncoDaily Medical Journal
2025
OncoDaily Medical Journal
adoptive cell therapy
CAR-T cells
Drug Resistance
immunotherapy
TCR-T cells
production-ready-file-url
[
Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019 Feb 18;94(Suppl 1):S3–S9.
]
[
Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023 May 15;14:1188049
]
[
Schuster SJ, Svoboda J, Chong EA, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017 Dec 28;377(26):2545-54.
]
[
Bouzianas D, Bouziana S. First pediatric B-acute lymphoblastic leukemia patient treated with anti-CD19 chimeric antigen receptor T-cell therapy: Long-term remission or early cure? Hum Vaccin Immunother. 2024 Dec 31;20(1):2321678.
]
[
Mariuzza RA, Agnihotri P, Orban J. The structural basis of T-cell receptor (TCR) activation: An enduring enigma. J Biol Chem. 2020 Jan 24;295(4):914-925.
]
[
Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021 Apr 6;11(4):69.
]
[
Sanomachi T, Katsuya Y, Nakatsura T, Koyama T. Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends. Cancers (Basel). 2025 Jun 11;17(12):1945.
]
[
Nie J, Zhou L, Tian W, et al. Deep insight into cytokine storm: from pathogenesis to treatment. Signal Transduct Target Ther. 2025 Apr 16;10(1):112.
]
[
Rangel Rivera GO, Knochelmann HM, Dwyer CJ, et al. Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy. Front Immunol. 2021 Mar 18;12:645242.
]
[
D’Errico I, Salvatore L, Murzilli S, et al. Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6603-8.
]
[
Bae T, Hallis SP, Kwak MK. Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer. Exp Mol Med. 2024 Mar;56(3):501-514.
]
[
Lee HN, Lee S, Hong J, et al. Novel FRET-based Immunological Synapse Biosensor for the Prediction of Chimeric Antigen Receptor-T Cell Function. Small Methods. 2025 Mar;9(3):e2401016.
]
[
Kosti P, Opzoomer JW, Larios-Martinez KI, et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med. 2021 Apr 9;2(4):100227.
]
[
Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 2010 Mar;16(3):133-44.
]
[
Gascoigne NR, Casas J, Brzostek J, Rybakin V. Initiation of TCR phosphorylation and signal transduction. Front Immunol. 2011 Dec 7;2:72.
]
[
Holler, P. D., Kranz, D. M. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity. 2003 Feb; 18(2), 255–264.
]
[
Alsaieedi AA, Zaher KA. Tracing the development of CAR-T cell design: from concept to next-generation platforms. Front Immunol. 2025 Jul 17;16:1615212.
]
[
Dagar G, Gupta A, Masoodi T, et al. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J Transl Med. 2023 Jul 7;21:449.
]
[
Xu X, Sun Q, Liang X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019 Nov 12;10:2664.
]
[
Nasiri, F., Safarzadeh Kozani, P., Salem, F. et al. Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies. Cancer Cell Int. 2025 Feb 24;25(1):64.
]
[
Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol. 2023 Aug;149(10):8131-8141.
]
[
Lin H, Yang X, Ye S, Huang L, Mu W. Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies. Biomed Pharmacother. 2024 Sep;178:117252.
]
[
Golikova EA, Alshevskaya AA, Alrhmoun S, Sivitskaya NA, Sennikov SV. TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges. J Transl Med. 2024 Oct 4;22(1):897.
]
[
Zhang B, Wu J, Jiang H, Zhou M. Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy. Cells. 2025; 14(5):320.
]
[
Anderson KG, Stromnes IM, Greenberg PD. Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell. 2017 Mar 13;31(3):311-325.
]
[
Kouro T, Himuro H, Sasada T. Exhaustion of CAR T cells: potential causes and solutions. J Transl Med. 2022 May 23;20(1):239.
]
[
Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, et al. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Front Immunol. 2023 Mar 20;14:1113882.
]
[
Cadinanos-Garai A, Flugel CL, Cheung A, Jiang E, Vaissié A, Abou-El-Enein M. High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing. Mol Ther. 2025 May 7;33(5):2291-2309.
]
[
Bartoszewska E, Tota M, Kisielewska M, et al. Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia. Cells. 2024 Sep 23;13(18):1596.
]
[
Aparicio-Pérez C, Carmona M, Benabdellah K, Herrera C. Failure of ALL recognition by CAR T cells: a review of CD19-negative relapses after anti-CD19 CAR-T treatment in B-ALL. Front Immunol. 2023 Apr 14;14:1165870.
]
[
Ellis GI, Sheppard NC, Riley JL. Genetic engineering of T cells for immunotherapy. Nat Rev Genet. 2021 Jul;22(7):427-447.
]
[
Choe JH, Watchmaker PB, Simic MS, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021 Apr 28;13(591):eabe7378.
]
[
Hamieh M, Mansilla-Soto J, Rivière I, Sadelain M. Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating. Cancer Discov. 2023 Apr 3;13(4):829-843.
]
[
Liu Z, Zhou Z, Dang Q, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics. 2022 Aug 29;12(14):6273-6290.
]
[
Gacerez AT, Arellano B, Sentman CL. How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy. J Cell Physiol. 2016 Dec;231(12):2590-8.
]
[
Nolan-Stevaux O, Smith R. Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies. Front Immunol. 2024 Nov 13;15:1490911
]
[
Nguyen A, Johanning G, Shi Y. Emerging Novel Combined CAR-T Cell Therapies. Cancers (Basel). 2022 Mar 9;14(6):1403.
]
[
Lajoie MJ, Boyken SE, Salter AI, et al. Designed protein logic to target cells with precise combinations of surface antigens. Science. 2020 Sep 25;369(6511):1637-1643.
]
[
Lei T, Wang Y, Zhang Y, et al. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia. 2024 Dec;38(12):2517-2543.
]
[
Lin P, Lin Y, Mai Z, et al. Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies. Theranostics. 2025 Jan 1;15(1):300-323.
]
[
Thaxton JE, Li Z. To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy. Hum Vaccin Immunother. 2014;10(11):3313-21.
]
[
Chmielewski M, Hombach AA, Abken H. Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol. 2013 Nov 11;4:371.
]
[
Cornel AM, Mimpen IL, Nierkens S. MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers (Basel). 2020 Jul 2;12(7):1760.
]
[
Yu J, Fu L, Wu R, et al. Immunocytes in the tumor microenvironment: recent updates and interconnections. Front Immunol. 2025 Apr 14;16:1517959.
]
[
Harris DT, Kranz DM. Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors. Trends Pharmacol Sci. 2016 Mar;37(3):220-230.
]
[
Liu X, Fang J, Huang S, et al. Tumor-on-a-chip: from bioinspired design to biomedical application. Microsyst Nanoeng. 2021 Jun 21;7:50.
]
[
Foeng J, Comerford I, McColl SR. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep Med. 2022 Feb 28;3(3):100543.
]
[
Yang J, Bergdorf K, Yan C, et al. CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth. Mol Cancer. 2023 Jun 3;22(1):92.
]
[
Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 Axis in Cancer Progression. Cancers (Basel). 2020 Jul 2;12(7):1765.
]
[
Caruana I, Savoldo B, Hoyos V, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015 May;21(5):524-9.
]
[
Kapałczyńska M, Kolenda T, Przybyła W, et al. 2D and 3D cell cultures – a comparison of different types of cancer cell cultures. Arch Med Sci. 2018 Jun;14(4):910-919.
]
[
Saratkar SY, Langote M, Kumar P, Gote P, Weerarathna IN, Mishra GV. Digital twin for personalized medicine development. Front Digit Health. 2025 Aug 7;7:1583466.
]
[
Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014 Oct 28;5:235.
]
[
Tan P, He L, Han G, Zhou Y. Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity. Trends Biotechnol. 2017 Mar;35(3):215-226.
]
[
Nguyen NT, Huang K, Zeng H, et al. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat Nanotechnol. 2021 Dec;16(12):1424-1434.
]
[
Ahmed EN, Cutmore LC, Marshall JF. Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells. Cancers (Basel). 2024 Sep 18;16(18):3186.
]
[
Andreu-Sanz D, Gregor L, Carlini E, Scarcella D, Marr C, Kobold S. Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis. J Immunother Cancer. 2025 Jun 12;13(6):e011698
]
[
Cattaneo CM, Dijkstra KK, Fanchi LF, et al. Tumor organoid-T-cell coculture systems. Nat Protoc. 2020 Jan;15(1):15-39.
]
[
Binnewies M, Roberts EW, Kersten K,et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018 May;24(5):541-550.
]
[
Jafari Nivlouei S, Soltani M, Carvalho J, Travasso R, Salimpour MR, Shirani E. Multiscale modeling of tumor growth and angiogenesis: Evaluation of tumor-targeted therapy. PLoS Comput Biol. 2021 Jun 23;17(6):e1009081.
]
[
Baena JC, Victoria JS, Toro-Pedroza A, et al. Smart CAR-T Nanosymbionts: archetypes and proto-models. Front Immunol. 2025 Aug 12;16:1635159.
]
[
Silva A, Vale N. Digital twins in personalized medicine: bridging innovation and clinical reality. J Pers Med. 2025 Oct;15:503.
]
[
Abdo L, Batista-Silva LR, Bonamino MH. Cost-effective strategies for CAR-T cell therapy manufacturing. Mol Ther Oncolytics. 2025 Jun 18;33:200980.
]
[
Dias J, Garcia J, Agliardi G, Roddie C. CAR-T cell manufacturing landscape-Lessons from the past decade and considerations for early clinical development. Mol Ther Methods Clin Dev. 2024 Apr 16;32(2):101250.
]
[
Holstein M, Mesa-Nuñez C, Miskey C, et al. Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors. Mol Ther. 2018 Apr 4;26(4):1137-1153.
]
[
Manuri PV, Wilson MH, Maiti SN, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010 Apr;21(4):427-37.
]
[
Su J, Zeng Y, Song Z, et al. Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies. J Hematol Oncol. 2025 Oct 24;18(1):90.
]
[
Mangani S, Kremmydas S, Karamanos NK. Mimicking the Complexity of Solid Tumors: How Spheroids Could Advance Cancer Preclinical Transformative Approaches. Cancers (Basel). 2025 Mar 30;17(7):1161.
]
[
Zhang Y, Liu Z, Wei W, Li Y. TCR engineered T cells for solid tumor immunotherapy. Exp Hematol Oncol. 2022 Jun 20;11(1):38.
]
[
Shang D, Zhou Z, Shi R, et al. Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives. Mol Cancer. 2025 Nov 4;24(1):281.
]